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We present a case of ventricular arrhythmia induced by a
premature ventricular beat with a short coupling interval in a
young patient with Brugada syndrome, vasodepressive
response to tilt test, and a structurally normal heart. A clear
vagal trigger appeared in all ventricular arrhythmia events.
The patient was implanted with an implantable cardioverter-
deﬁbrillator (ICD).
Case report
A 44-year-old man was admitted to the hospital after 2
episodes of syncope. Upon waking up at midnight, the
patient proceeded to urinate, went back to his bed, and
passed out. His wife noticed that he was not responding and
started cardiopulmonary resuscitation. After about 2
minutes, the patient started to respond. An emergency
medical services team was called, but before their arrival
the patient experienced a shorter similar episode. When
emergency medical services arrived he was alert, but felt
fatigue. His blood pressure was normal. An electrocardio-
gram (ECG) at home showed slow atrial ﬁbrillation (AF)
with short–coupling interval premature ventricular contrac-
tions (280 ms) and ST elevation in V2-V3 and weak “coved-
type” ST elevation in V1, compatible with Brugada syn-
drome (Figure 1). The AF converted spontaneously to sinus
rhythm over the next few hours. The ﬁrst ECG in sinus
rhythm was recorded in the morning with right bundle
branch block pattern and ST elevation compatible with
Brugada syndrome, together with short-coupled ventricular
premature beats (VPBs) (Figure 2). Later ECGs did not
indicate a Brugada pattern.
A 24-hour Holter monitor demonstrated sinus rhythm
(average of 80 beats per minute [bpm]) and 320 VPBs with
very short coupling intervals, less than 280 ms. An echo-
cardiogram demonstrated normal left ventricular systolic
function and normal structure and function of the heart
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test, which was positive.
A tilt table test was performed because of the clinical
picture of the neurocardiogenic syncope. At baseline the
heart rate was 80 bpm and the blood pressure was 139/90
mm Hg. During the orthostatic challenge the heart rate
gradually increased and the blood pressure decreased.
After 5 minutes, the patient complained of dizziness; his
heart rate increased to 131 bpm, and his blood pressure
decreased to 110/70 mm Hg. At minute 9 the patient had
frank syncope, with a heart rate of 142 bpm and non-
measurable blood pressure (the last measured blood
pressure was 75/50 mm Hg). The patient was returned
to the supine position and regained consciousness.
A diagnosis of vasodepressive syncope was made, and
exaggerated orthostatic tachycardia was noted. Electro-
physiological study (EPS) revealed a relatively long HV
interval of 60 ms. A programmed electrical stimulation
from both the right ventricular apex and outﬂow tract was
conducted with stimulation up to 350/160/160/150/150 ms
with 1-to-1 conduction without induction of any ventric-
ular arrhythmia. We have not performed genetic testing in
this patient.
An ICD was implanted because of the spontaneous
Brugada at presentation and very short–coupling interval
VPBs, despite the noninducible EPS and the demonstration
of the vasodepressive (vagal) syncope. The patient was
discharged with beta blocker therapy. Three weeks later,
the patient experienced an electrical shock delivered by the
ICD at 6:33 AM. The patient urinated and washed his face
with cool water and felt the electrical shock without any
other symptoms or syncope. An ICD interrogation (Figure 3)
demonstrated that a VPB with a short coupling interval (260
ms) induced a ventricular ﬁbrillation (VF), which converted
into sinus rhythm with 20.4 J. Of note, slowing of the sinus
rhythm (from 115 to 81 bpm) preceded the VPB. On the
same day at 1 PM, the patient experienced another electrical
shock. This was during urination. Again an ICD inter-
rogation showed a VPB with a short coupling interval
(280 ms) that induced VF. The patient was hospitalized
and 1500 mg of quinidine daily was started. The patientpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.08.016
KEY TEACHING POINTS
 The likelihood of ventricular arrhythmias in
Brugada syndrome is increased at times when vagal
tone is high. Thus, arrhythmic syncope in these
patients can be confused with neurocardiogenic
syncope, especially if Brugada electrocardiogram
signs are intermittent.
 The recovery phase of the exercise test and Holter
recordings during sleep provide a good opportunity
to observe vagally mediated ST elevations and
could provide important diagnostic information
whenever Brugada syndrome is suspected.
 Atrial ﬁbrillation is the most common atrial
arrhythmia in patients with Brugada syndrome and
may be its ﬁrst manifestation; it is associated with
unfavorable prognosis. Brugada syndrome should
be excluded in young patients with atrial
ﬁbrillation and normal heart and
electrocardiogram, because administration of class
IC antiarrhythmic agents may cause ventricular
arrhythmias and cardiac arrest.
531Teodorovich et al Vagally Mediated VF in Brugada Syndrometolerated the quinidine well, with a blood drug level in the
expected range without prolongation of the QTc interval.
The only ventricular arrhythmia events that were recorded byFigure 1 Electrocardiogram recorded by emergency medical services team de
premature beats (280 ms) and ST elevation in V2-V3 and weak “coved-type” ST ethe ICD over the 11-year follow-up were episodes of
nonsustained ventricular tachycardia (VT) during several
days when the patient discontinued quinidine owing to a
shortage at the local pharmacy. A 24-hour Holter monitor
performed at that time (2010) demonstrated ST elevations
that were present at night (Figure 4). These ST elevations
were not rate dependent because they were absent from the
daytime recordings during both slow and fast heart rate, so
they were presumably vagally mediated.Discussion
Brugada syndrome is a distinct clinical and electrocardio-
graphic syndrome associated with syncopal episodes and
sudden cardiac death in patients with an ECG that demon-
strates ST elevation in right precordial leads.1 It has an
autosomal dominant pattern of inheritance2; more than 250
mutations in 13 genes have been described, leading to an
imbalance between depolarizing Na and Ca currents and
repolarizing the K (Ito) current. The resultant right ventricular
transmural inhomogeneity causes short-coupled VPBs and
then polymorphic VT or VT through the phase 2 reentry
mechanism.3 Sodium channel blockers are used to unmask a
Brugada ECG pattern in suspected individuals.4 History
of cardiac arrest or syncope, male sex, and spontaneous
AF have all been demonstrated to have prognostic
signiﬁcance.5,6 Management includes ICD implantation,7
quinidine to prevent arrhythmias and recurrent ICD shocks,8
and catheter ablation in selected patients.9monstrating slow atrial ﬁbrillation with short–coupling interval ventricular
levation in V1 compatible with Brugada syndrome.
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Figure 2 Electrocardiogram in sinus rhythm demonstrates ST elevations in V1-V3 consistent with Brugada syndrome together with short-coupled (250 msec)
ventricular premature beats.
Heart Rhythm Case Reports, Vol 2, No 6, November 2016532Our patient is a prime example that a clear parasympa-
thetic activation combined with very early VPB induces VF.
The transient and intermittent Brugada pattern on ECG can
be related to vagal activity changes. In our case all syncopal
events and documented ventricular arrhythmia were associ-
ated with increased vagal activity such as urination, washing
with cool water, and postural changes. Moreover, a slowed
heart rate preceded VPB-induced ventricular arrhythmia on
the ICD recording. In addition, our patient demonstrated a
vasodepressive response during the head-up tilt table test and
intermittent ST elevation (type I Brugada during sleep) on
the Holter recording (Figure 4).
Increased vagal tone may lead to more pronounced ST-
segment elevation and an increased likelihood of arrhyth-
mias in Brugada patients owing to decreasing ICa.
10 Ace-
tylcholine was demonstrated to augment ST-segment
elevation in patients with Brugada syndrome. Higher vagal
tone also explains the higher incidence of arrhythmias at
night in these patients.11,12 An early study demonstrated that
in 6 patients with transient rSR0 pattern with ST elevation in
right precordial leads and episodes of VF, agents that block
sympathetic activation and increase parasympathetic
activation caused more pronounced ST elevation and easier
VT/VF inducibility on EPS, whereas sympathomimetic
and vagolytic agents had the opposite effect.13 Moreover,in some of these patients, Holter ECG monitoring demon-
strated an increased high-frequency component (marking
increased vagal tone) just before VF (as in our case;
Figures 3 and 4). One study demonstrated that patients with
Brugada syndrome who had increased ST elevation in
V1-V2 during the recovery stage of the exercise test also
had increased heart rate recovery (as a sign of increased
vagal activity). These patients had signiﬁcantly more ven-
tricular arrhythmias and sudden cardiac death (44% vs 17%)
than patients with Brugada syndrome without these
ﬁndings on the exercise test.14 Another study demonstrated
much higher frequency of ST-segment augmentation in
right precordial leads (69% vs 7%) in patients with a
positive response to the tilt test.15 Ikeda et al 16 proposed a
full stomach test to identify patients at risk for Brugada
syndrome.
Our patient had short-coupled VPBs (260–280 ms),
which initiated episodes of VF. While some reports demon-
strated rather long-coupled VPBs initiating ventricular
arrhythmias in these patients,13,17 other studies demonstrated
short-coupled VPBs causing ventricular arrhythmias in both
experimental models and clinical studies in Brugada syn-
drome.10,18–19 Short-coupled VPB is consistent with the
phase 2 reentry hypothesis, which is itself a result of
transmural inhomogeneity.10
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Figure 3 An implantable cardioverter-deﬁbrillator interrogation demonstrates a ventricular premature beat (VPB) with a short coupling interval (260 ms),
which induced a ventricular ﬁbrillation, which converted into sinus rhythm with 20.4 J. Slowing of the heart rate (from 520 to 740 msec) precedes a short-
coupled VPB.
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rent VF in patients with Brugada syndrome is consistent with
a vagal tone proarrhythmic effect in these patients.20,21
Quinidine is effective in restoring the epicardial action
potential dome and normalizing the ST-segment elevation
and preventing phase 2 reentry.8,22 Our patient had 2
syncopal episodes and 2 documented VF events in a period
of 3 weeks. Daily treatment with quinidine prevented
any syncopal or ventricular arrhythmia event for more than
11 years.
Our patient presented with AF after syncope. AF is the
most common atrial arrhythmia in patients with Brugada
syndrome and may be its ﬁrst manifestation23,24; it is
associated with an unfavorable prognosis.6 Brugada syn-
drome should be excluded in young patients with AF and
normal heart and ECG, because the administration of class
IC antiarrhythmic agents may cause ventricular arrhythmias
and cardiac arrest.In conclusion, our case shows many faces of Brugada
syndrome, including syncopal events, AF at presentation, and
an intermittent Brugada pattern on the ECG. The uniqueness of
the current case is a clear demonstration of vagal-mediated
Brugada’s ST elevation, short–coupling interval VPB, induction
of VF, and response to quinidine. The efﬁcacy of the quinidine in
this patient may be due not only to the inhibition of the Ito current,
but also to its known vagolytic effect.25,26
Increased vagal activity increased the endocardial-
epicardial heterogeneity and predisposed the patient to VF.
The combination of ICD implantation to terminate VF
episodes and quinidine therapy to prevent the recurrence of
VF has been proven to be effective in our patient.
Because ECG signs of Brugada syndrome may be inter-
mittent (as it was in our case), the pharmacologic challenge to
exclude Brugada syndrome should be strongly considered in
patients presenting with “vagal” syncope, especially a recurrent
one. Presence of AF makes this testing even more compulsory.
Time: 14:49:53, Heart rate 114bpm, no ST elevation
Time: 20:08:14 Heart rate 62bpm, no ST elevation
Time: 03:09:38 Heart rate 92bpm, 
Brugada type I ST elevation
Figure 4 A 24-hour Holter monitor performed at 8:10 PM demonstrates that ST elevations are much more prominent at night (Brugada type I pattern). The
changes in the magnitude of the ST elevations are not rate dependent (ST elevations are much less prominent in the daytime recordings during both slow and fast
heart rates).
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